Tallac Therapeutics
Em Abellana has a diverse work experience spanning over three decades. They began their career as a Management Analyst at San Mateo County in 1989 and stayed in that role until 2000. Following this, they joined Exelixis as a Senior Accountant and worked there until 2005. From 2005 to 2012, Em served as a Senior Manager in Accounting at KAI Pharmaceuticals, which was a subsidiary of Amgen, Inc. They then worked at Labrys Biologics, Inc. as a Senior Manager in Accounting from 2013 to 2014. In 2014, Em became a Financial Consultant at Relypsa for a short period of time. In 2015, they moved on to ALX Oncology where they served as the Senior Director of Finance and Controller until 2020. Currently, they hold the position of Senior Director of Finance at Tallac Therapeutics, which they started in 2020.
Em Abellana has a Bachelor of Science (BS) degree in Accounting from Far Eastern University.
This person is not in any teams
Tallac Therapeutics
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer. Tallac’s pipeline of immunotherapy candidates are derived from the company’s novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent Toll-like receptor (TLR9) agonist (T-CpG) for targeted immune activation via systemic administration. Several TRAAC molecules are in various stages of discovery and preclinical development.